|
TOX4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.97428748297079E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.15669753961856E-11 |
| Normal-vs-Stage2 |
3.5942000000011E-05 |
| Normal-vs-Stage3 |
1.37410083311806E-11 |
| Normal-vs-Stage4 |
4.31209956630596E-10 |
| Stage1-vs-Stage2 |
4.006000E-01 |
| Stage1-vs-Stage3 |
2.684400E-01 |
| Stage1-vs-Stage4 |
2.566000E-01 |
| Stage2-vs-Stage3 |
1.258160E-01 |
| Stage2-vs-Stage4 |
1.416030E-01 |
| Stage3-vs-Stage4 |
8.951200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.92494933723719E-13 |
| Normal-vs-AfricanAmerican |
3.339600E-03 |
| Normal-vs-Asian |
7.77150000019766E-07 |
| Caucasian-vs-AfricanAmerican |
8.795700E-02 |
| Caucasian-vs-Asian |
4.159600E-01 |
| AfricanAmerican-vs-Asian |
3.400000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.77390341199657E-11 |
| Normal-vs-Female |
1.51020307370686E-11 |
| Male-vs-Female |
2.795800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.60040003471806E-09 |
| Normal-vs-Age(41-60Yrs) |
2.67770028372638E-10 |
| Normal-vs-Age(61-80Yrs) |
1.27829968832316E-11 |
| Normal-vs-Age(81-100Yrs) |
1.078060E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.302200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.340200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.296800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.423200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.491400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.603600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.741740E-02 |
| Classical-VS-Follicular |
7.267700E-02 |
| Classical-VS-Other |
7.425600E-02 |
| Classical-VS-Normal |
1.43330014523713E-10 |
| Tall-VS-Follicular |
4.040200E-01 |
| Tall-VS-Other |
5.567000E-01 |
| Tall-VS-Normal |
1.87430004849887E-09 |
| Follicular-VS-Other |
4.391600E-01 |
| Follicular-VS-Normal |
1.4405999948508E-08 |
| Other-VS-Normal |
1.621110E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.69739999833496E-10 |
| Normal-vs-N1 |
5.75419711879022E-11 |
| N0-vs-N1 |
7.897900E-02 |
|
|
